CO6561780A2 - Fromas polomorficas , cristalinas y de mesofase de 2-(5- bromo-4(4-ciclopropilnaftalen -1-il) -ah-1,2,4- triazol-3-iltio)acetato de sodio, y usos de las mismas - Google Patents
Fromas polomorficas , cristalinas y de mesofase de 2-(5- bromo-4(4-ciclopropilnaftalen -1-il) -ah-1,2,4- triazol-3-iltio)acetato de sodio, y usos de las mismasInfo
- Publication number
- CO6561780A2 CO6561780A2 CO12109744A CO12109744A CO6561780A2 CO 6561780 A2 CO6561780 A2 CO 6561780A2 CO 12109744 A CO12109744 A CO 12109744A CO 12109744 A CO12109744 A CO 12109744A CO 6561780 A2 CO6561780 A2 CO 6561780A2
- Authority
- CO
- Colombia
- Prior art keywords
- triazol
- crystalline
- bromo
- mesophase
- sodium acetate
- Prior art date
Links
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 title abstract 3
- 235000017281 sodium acetate Nutrition 0.000 title abstract 3
- 239000001632 sodium acetate Substances 0.000 title abstract 3
- -1 4-cyclopropylnaphthalen-1-yl Chemical group 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29360210P | 2010-01-08 | 2010-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6561780A2 true CO6561780A2 (es) | 2012-11-15 |
Family
ID=44306123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12109744A CO6561780A2 (es) | 2010-01-08 | 2012-06-29 | Fromas polomorficas , cristalinas y de mesofase de 2-(5- bromo-4(4-ciclopropilnaftalen -1-il) -ah-1,2,4- triazol-3-iltio)acetato de sodio, y usos de las mismas |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8524754B2 (enExample) |
| EP (1) | EP2521716B1 (enExample) |
| JP (1) | JP5696346B2 (enExample) |
| KR (1) | KR20120104627A (enExample) |
| CN (1) | CN102741234B (enExample) |
| AU (1) | AU2011203708B2 (enExample) |
| BR (1) | BR112012016795A2 (enExample) |
| CA (1) | CA2785200C (enExample) |
| CL (1) | CL2012001841A1 (enExample) |
| CO (1) | CO6561780A2 (enExample) |
| EA (1) | EA020183B1 (enExample) |
| ES (1) | ES2563207T3 (enExample) |
| MX (1) | MX2012007925A (enExample) |
| MY (1) | MY161482A (enExample) |
| NZ (1) | NZ600984A (enExample) |
| PH (1) | PH12012501391A1 (enExample) |
| SG (1) | SG182404A1 (enExample) |
| TW (1) | TWI451867B (enExample) |
| WO (1) | WO2011085009A2 (enExample) |
| ZA (1) | ZA201204938B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560642A4 (en) * | 2010-03-30 | 2013-12-18 | Ardea Biosciences Inc | TREATMENT OF GICHT |
| ES2670700T3 (es) * | 2010-06-15 | 2018-05-31 | Ardea Biosciences, Inc. | Tratamiento de gota e hiperuricemia |
| MY172534A (en) * | 2010-12-30 | 2019-11-29 | Ardea Biosciences Inc | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
| ES2704233T3 (es) | 2011-11-03 | 2019-03-15 | Ardea Biosciences Inc | Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo |
| AR091651A1 (es) * | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
| CN103524440B (zh) * | 2013-10-15 | 2015-09-09 | 苏州鹏旭医药科技有限公司 | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 |
| CN103613552A (zh) * | 2013-12-02 | 2014-03-05 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
| CN103588716A (zh) * | 2013-11-22 | 2014-02-19 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法 |
| CA2931430A1 (en) * | 2013-11-22 | 2015-05-28 | Crystal Pharmatech Co., Ltd. | Crystalline forms of lesinurad and its sodium salt |
| WO2015095703A1 (en) | 2013-12-20 | 2015-06-25 | Crystal Pharmatech, Inc. | Novel salts and co-crystals of lesinurad |
| CN103626710A (zh) * | 2013-12-20 | 2014-03-12 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法 |
| CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
| CN105315218A (zh) * | 2014-07-17 | 2016-02-10 | 天津药物研究院 | 一种制备lesinurad中间体1-萘基三唑硫酮的方法 |
| CN105622427A (zh) * | 2014-10-31 | 2016-06-01 | 天津药物研究院有限公司 | 一种制备lesinurad中间体4-环丙基-1-萘胺的方法 |
| CN105820130B (zh) * | 2015-01-08 | 2018-06-22 | 天津药物研究院有限公司 | 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
| CN105985296B (zh) * | 2015-02-13 | 2018-10-16 | 天津药物研究院有限公司 | 一种可以工业化的lesinurad中间体1-萘基三唑硫酮的精制工艺 |
| CN105622531A (zh) | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | 轴手性异构体及其制备方法和制药用途 |
| CN104817509B (zh) * | 2015-04-13 | 2019-05-17 | 安徽省逸欣铭医药科技有限公司 | Lesinurad类似物及其制备方法和医药用途 |
| CN106187926B (zh) * | 2015-04-30 | 2018-11-27 | 天津药物研究院有限公司 | 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
| EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
| CN104987311A (zh) * | 2015-06-30 | 2015-10-21 | 安徽万邦医药科技有限公司 | 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯 |
| CN105017168A (zh) * | 2015-07-01 | 2015-11-04 | 安徽万邦医药科技有限公司 | 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法 |
| CN105153056A (zh) * | 2015-07-01 | 2015-12-16 | 安徽万邦医药科技有限公司 | 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法 |
| WO2017036884A1 (en) | 2015-08-28 | 2017-03-09 | Sandoz Ag | A lesinurad, free form / lesinurad ethyl ester co-crystal |
| CN105566237B (zh) * | 2016-03-01 | 2018-05-18 | 山东大学 | 一种治疗痛风的三唑巯乙酸类化合物的制备方法 |
| CN107337649B (zh) * | 2016-04-29 | 2020-10-16 | 四川科伦药物研究院有限公司 | 一种乙酸钠水合物无定型及其制备方法和用途 |
| EP3281941B1 (en) | 2016-08-11 | 2019-07-24 | Zentiva K.S. | Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid |
| WO2018085932A1 (en) | 2016-11-10 | 2018-05-17 | Apotex Inc. | Novel crystalline forms of lesinurad |
| CN106632108A (zh) * | 2016-12-14 | 2017-05-10 | 湖南欧亚生物有限公司 | 一种来司诺雷的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| ME01512B (me) | 2004-08-25 | 2014-04-20 | Ardea Biosciences Inc | S-triazolil alfa-merkaptoacetanilida kao inhibitori HIV reversne transkriptaze |
| BRPI0819847B1 (pt) | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| CN102186832B (zh) * | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
| MY172534A (en) | 2010-12-30 | 2019-11-29 | Ardea Biosciences Inc | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
-
2011
- 2011-01-05 AU AU2011203708A patent/AU2011203708B2/en not_active Ceased
- 2011-01-05 EP EP11732089.5A patent/EP2521716B1/en active Active
- 2011-01-05 EA EA201270676A patent/EA020183B1/ru not_active IP Right Cessation
- 2011-01-05 US US13/375,607 patent/US8524754B2/en not_active Expired - Fee Related
- 2011-01-05 MY MYPI2012003108A patent/MY161482A/en unknown
- 2011-01-05 ES ES11732089.5T patent/ES2563207T3/es active Active
- 2011-01-05 SG SG2012050100A patent/SG182404A1/en unknown
- 2011-01-05 CA CA2785200A patent/CA2785200C/en not_active Expired - Fee Related
- 2011-01-05 NZ NZ600984A patent/NZ600984A/xx not_active IP Right Cessation
- 2011-01-05 MX MX2012007925A patent/MX2012007925A/es active IP Right Grant
- 2011-01-05 KR KR1020127020834A patent/KR20120104627A/ko not_active Ceased
- 2011-01-05 BR BR112012016795-2A patent/BR112012016795A2/pt not_active Application Discontinuation
- 2011-01-05 JP JP2012548092A patent/JP5696346B2/ja not_active Expired - Fee Related
- 2011-01-05 WO PCT/US2011/020233 patent/WO2011085009A2/en not_active Ceased
- 2011-01-05 CN CN201180005688.7A patent/CN102741234B/zh not_active Expired - Fee Related
- 2011-01-05 PH PH1/2012/501391A patent/PH12012501391A1/en unknown
- 2011-01-07 TW TW100100688A patent/TWI451867B/zh not_active IP Right Cessation
-
2012
- 2012-06-29 CO CO12109744A patent/CO6561780A2/es not_active Application Discontinuation
- 2012-07-02 ZA ZA2012/04938A patent/ZA201204938B/en unknown
- 2012-07-06 CL CL2012001841A patent/CL2012001841A1/es unknown
-
2013
- 2013-07-30 US US13/954,736 patent/US20130345271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1172622A1 (zh) | 2013-04-26 |
| EA201270676A1 (ru) | 2013-01-30 |
| EP2521716A4 (en) | 2013-07-10 |
| EP2521716B1 (en) | 2015-12-30 |
| PH12012501391A1 (en) | 2012-10-29 |
| JP5696346B2 (ja) | 2015-04-08 |
| EA020183B1 (ru) | 2014-09-30 |
| JP2013516473A (ja) | 2013-05-13 |
| US8524754B2 (en) | 2013-09-03 |
| SG182404A1 (en) | 2012-08-30 |
| WO2011085009A2 (en) | 2011-07-14 |
| AU2011203708B2 (en) | 2013-08-01 |
| US20120129903A1 (en) | 2012-05-24 |
| CN102741234B (zh) | 2015-11-25 |
| MX2012007925A (es) | 2012-08-03 |
| CA2785200A1 (en) | 2011-07-14 |
| MY161482A (en) | 2017-04-14 |
| ZA201204938B (en) | 2014-12-23 |
| CL2012001841A1 (es) | 2013-08-23 |
| TWI451867B (zh) | 2014-09-11 |
| KR20120104627A (ko) | 2012-09-21 |
| WO2011085009A3 (en) | 2011-11-10 |
| CA2785200C (en) | 2015-02-24 |
| NZ600984A (en) | 2013-10-25 |
| BR112012016795A2 (pt) | 2020-09-01 |
| ES2563207T3 (es) | 2016-03-11 |
| AU2011203708A1 (en) | 2012-07-26 |
| TW201143767A (en) | 2011-12-16 |
| CN102741234A (zh) | 2012-10-17 |
| EP2521716A2 (en) | 2012-11-14 |
| US20130345271A1 (en) | 2013-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
| MX2012007925A (es) | Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas. | |
| EA201391158A8 (ru) | Диаминиевые соли фенотиазина и их применение | |
| CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
| WO2014008295A8 (en) | Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid | |
| CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| UA111770C2 (uk) | Інгібітори бромдомену | |
| IN2014DN09352A (enExample) | ||
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| WO2011006935A3 (en) | Tetrazole derivatives | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| IN2014CN04530A (enExample) | ||
| ECSP11011555A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
| WO2010139981A3 (en) | Processes for preparing crystalline forms of dasatinib | |
| CO6321280A2 (es) | Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| WO2009109501A3 (en) | Ocular pharmaceutical compositions | |
| EP2400848A4 (en) | CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS | |
| LT3395796T (lt) | (3s,3s') 4,4'-disulfandiil-bis-(3-aminobutan-1-sulfonrūgšties) kristalinė trihidrato forma | |
| BR112012016744A2 (pt) | "método e kits para detectar fatores de risco para o desenvolvimento de osteonecrose da mandíbula e métodos de tratamento da mesma" | |
| MX2012007426A (es) | Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos. | |
| JP2011512405A5 (enExample) | ||
| AR091402A1 (es) | Profarmacos de acido fosforadimico | |
| WO2011161245A3 (en) | Polymorphs of febuxostat | |
| AR101487A1 (es) | Formas cristalinas de un modulador de receptor de estrógeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |